DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis ...

Compare the best Samsung Watch CGM apps and Wear OS tools for blood sugar readings, including Dexcom G6, Gluroo, and xDrip+.

FDA clears Dexcom Stelo as the first OTC CGM for children, raising new questions around app access, caregiver oversight, ...

AI may help smartwatches make glucose data more useful through better predictions, pattern detection, and personalized health ...

DexCom's FDA-cleared Stelo OTC glucose biosensor now covers children aged above 2 years not using insulin, expanding access to smartphone-linked CGM insights.

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom yesterday and set a price target of $85.00. The company’s shares closed yesterday at $76.62. Introducing Ti ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dexcom , Revolution Medicines and Incyte . Introducing TipRanks MCP for Agents. Deliver instituti ...

Azul, the trusted leader in enterprise Java for today's AI and cloud-first world, today announced that EWE AG, one of Germany's leading energy and infrastructure companies, has cut its Java licensing ...

Insulet (PODD) stock and DexCom (DXCM) receive new Buy ratings from Deutsche Bank while Tandem Diabetes Care (TNDM) stock ...

June 6 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not ...

Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...

Continuous glucose monitors have become popular among those who need to track their glucose levels because they're painless ...